TrialThe oncologist2021

Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma.

Dickran Kazandjian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.